Recent

% | $
Quotes you view appear here for quick access.

AGFEED INDUSTRIES Message Board

neii 76 posts  |  Last Activity: Apr 22, 2016 6:02 PM Member since: Mar 20, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Intracostal dumping all their shares

    by toxlcdumper1 Apr 20, 2016 9:41 PM
    neii neii Apr 22, 2016 6:02 PM Flag

    I took a dump today. But it has nothing to do with ATHX.

    Sentiment: Strong Buy

  • Phase II (3 Programs)
    Myocardial infarction; Respiratory distress syndrome; Stroke

    Phase I (2 Programs)
    Graft-versus-host disease; Transplant rejection

    Preclinical (8 Programs)
    Brain injuries; Diabetes mellitus; Heart failure; Mucopolysaccharidosis I; Multiple sclerosis; Parkinson's disease; Peripheral vascular disorders; Spinal cord injuries

    Discontinued (1 Program)
    Ulcerative colitis

    Sentiment: Strong Buy

  • Reply to

    $VCEL crushed by clinical trial results

    by ezskeyewater Apr 9, 2016 10:00 AM

    Agreed. Even if they got it into the peri-vascular space of the vessel or like ismyelocel injected in into the left ventricle perfectly---I think there is still a low chance of meaningful efficacy. But I hope the trial proves me wrong. THIS IS WITH AMI NOT STROKE.

    Sentiment: Strong Buy

  • Reply to

    $VCEL crushed by clinical trial results

    by ezskeyewater Apr 9, 2016 10:00 AM
    neii neii Apr 9, 2016 12:42 PM Flag

    Unlike stoke, AMI is very difficult to treat and get long-term improvements in heart function for. When that portion of the heart muscle dies, for some reason--so far stem cells were not able to bring back function even after 12 months.....see Neostem clinical trial also. Not saying Multistem can't do it, but the odds are not as strong with working for AMI as it has done with ischemic stroke. If Multistem works for AMI, ATHX will be a largest appreciating stock in the history of the stock market.....but I'm even doubtful it will work for AMI....at least a long shot.

    Sentiment: Strong Buy

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM

    No disagreement here. Conditional approval thus year, and full approval in 2020. With conditional approval, product will be available to the public in Japan and Healiis receives insurance reimbursement. ATHX subsequently gets its first royalty payment.

    Sentiment: Strong Buy

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM

    SEE BELOW

    Sentiment: Strong Buy

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM

    Read below an except from an article by Alexey Bersenev in Cell Trials:
    " the regulatory pathway for commercial cellular products is significantly accelerated by skipping of typical “Phase 3 trial” and allowance of marketing authorization after demonstration of safety and some (minimal) signs of efficacy (Phases 1/2). In this “accelerated scheme” the cell therapeutic candidate will be available to patients faster and company will able to generate profit and survive."

    Sentiment: Strong Buy

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM

    2018.....LOL.....Conditional approval will be in 2016 !!!

    Sentiment: Strong Buy

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM

    2 years ago Japan has passed a new law for regulation of Regenerative Medicine. Under this law, the regulatory pathway for commercial cellular products is significantly accelerated by skipping of typical “Phase 3 trial” and allowance of marketing authorization after demonstration of safety and some (minimal) signs of efficacy (Phases 1/2). In this “accelerated scheme” the cell therapeutic candidate will be available to patients faster and company will able to generate profit and survive. It is important to keep in mind that this accelerated approval is conditional – in the next few years after market authorization, company-developer obligated to provide clinical data on efficacy. If there will be strong evidence for the efficacy, product will stay on the market. Professionals were watching this regulatory change in Japan with great interest and, most of us are very sympathetic of this approach.
    In September of 2015, the new Regenerative Medicine law yielded the first results – two cell products were approved on Japanese market. The first product is TemCell (by JCR Pharmaceuticals) – allogeneic mesenchymal stromal cells for GVHD. The second product is HeartSheet (by Terumo) – autologous skeletal muscle cells for heart failure. Two months after market authorization, both product have received price tag and reimbursement decision. TemCell is priced ~ $115,000 – $170,000 USD (depending on total number of doses infused) and HeartSheet is priced ~ $120,000 USD. Depending on insurance plans, Japanese patients will still pay out of pocket anything between 5% to 30% of the product price.

    Sentiment: Strong Buy

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM
    neii neii Apr 8, 2016 12:44 PM Flag

    Wish me the best of luck....thanks, please continue to enlarge your short position, I dare you to!

    Sentiment: Strong Buy

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM
    neii neii Apr 8, 2016 12:36 PM Flag

    PMDA could give Multistem a conditional approved by the end of the summer for use in Japan only.

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM
    neii neii Apr 8, 2016 12:28 PM Flag

    Healios KK (4593.T)
    Check out their Ticker on Reuters

  • Reply to

    Product works

    by neii Apr 7, 2016 11:25 PM
    neii neii Apr 8, 2016 12:17 PM Flag

    Evidence is pretty much overwhelming that Multimstem will be used in Japan.....and yes they are dumb because on pharmacological drugs a mere 2% greater survival rate over standard of care in a double-blind study would mean product approval to the market whereas with cell therapy, it means, "still don't believe it"..........what the #$%$* are they going to say this summer after Healios starts using this in Japan, by the way Healios which is a mid cap company just went up 68% in the last couple months on the news and 3.63% just today. Think about it hedge fund smart man, why would an insider "Healios' have such stock appreciation if it wasn't almost a foregone certainty that Multistem will be approved and in use for the treatment stroke in Japan by this summer. I think they know more than you do!

    Sentiment: Strong Buy

  • Dumb hedge fund shorting this will get fried like they never seen before. Check out latest CEO interview on YouTube.

    Sentiment: Strong Buy

  • Reply to

    Why I have....

    by neii Mar 17, 2016 10:11 PM

    You are the man anticol!!!

  • With an excellent 1year outcome, Multistem will be adopted for use in Japan this year as treatment for stroke as it is the nation"s greatest unmet medical need. Betting against this likely outcome is silly as there are better short opportunities out there.

    Sentiment: Strong Buy

  • We're being hit with substantial volume of short selling.

    This is coordinated, and I don't know what the budget for this short position is.

    Because I'm not trading ATHX, rather I'm investing in it, so I'm not going to reduce my position.

    Calling a possible short term downside to support to $2.18 and 50% chance of hitting $2 in the next few sessions before rebounding. Followed by consolidation and a trek up the mountain again!

    Good news can come out in the next several weeks and the shorts will have to take profits into this move, or take profits into the next AF hit piece, because downside momentum will fade with few selling into a fabricated "panic"..

    Sentiment: Strong Buy

  • Reply to

    Strong Finish

    by neii Mar 22, 2016 7:26 PM
    neii neii Mar 25, 2016 12:31 PM Flag

    LOL....guess saga continues Monday.

    Sentiment: Strong Buy

  • Reply to

    Strong Finish

    by neii Mar 22, 2016 7:26 PM
    neii neii Mar 24, 2016 7:06 PM Flag

    Shorts lost today and based on the after-market price as I write this, they'll lose tomorrow as well !! Fridays are a #$%$ for short traders....can't hold this over the weekend. We are headed into periods of volatility like this for a few more months until some of the major catalysts kick in, but the trend will be higher every month---we're going to move to levels we should have been in the first place----conservatively $10+ by the end of the year!!

    Sentiment: Strong Buy

  • Reply to

    Exosomes!

    by wall_street_titan Mar 21, 2016 9:53 PM
    neii neii Mar 24, 2016 6:17 PM Flag

    I believe you are correct too.....messenger Deoxyribonucleic acids are within exosomes as well, but they carry partial blueprints that can be used in generating functional proteins once delivered inside the new cells.